No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
RPTX Repare Therapeutics
- 3.810
- -0.090-2.31%
Trading Jul 22 11:38 ET
161.72MMarket Cap-3463P/E (TTM)
4.050High3.760Low32.87KVolume3.970Open3.900Pre Close126.45KTurnover0.19%Turnover RatioLossP/E (Static)42.45MShares13.85052wk High0.70P/B67.31MFloat Cap2.98052wk Low--Dividend TTM17.67MShs Float46.440Historical High--Div YieldTTM7.44%Amplitude2.980Historical Low3.847Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Bloom Burton Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $15
Bloom Burton analyst David Martin PhD maintains $Repare Therapeutics(RPTX.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 43
TD Cowen Maintains Repare Therapeutics(RPTX.US) With Buy Rating
TD Cowen analyst Marc Frahm maintains $Repare Therapeutics(RPTX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.8% and a total average return of 15.2% over the
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Morgan Stanley analyst Jeffrey Hung maintains $Repare Therapeutics(RPTX.US)$ with a hold rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 54.4
Express News | Repare Therapeutics Inc - Overall Response of 18.2% in Heavily Pretreated Patients
Express News | Repare Therapeutics Inc: Safety Profile of Combination Consistent With Folfiri Alone
Express News | Repare Therapeutics Announces Positive Initial Data at Esmo Gi From Phase 1 Minotaur Trial Evaluating Lunresertib in Combination With Folfiri
Comments
$Repare Therapeutics(RPTX.US$ ⏰静待回调，📌首轮加仓价@3.21🔥
——参考资讯——
🔺Repare Therapeutics is a clinical-stage precision oncology company that focuses on developing novel cancer therapies using a synthetic lethality approach. The company leverages its proprietary SNIPRx® platform, which employs genome-wide CRISPR-based screening to identify synthetic lethal gene pairs. This allows them to target specific genetic alterations in tumors, thereby developing highly targeted therapies for cancer patients (https:...
——参考资讯——
🔺Repare Therapeutics is a clinical-stage precision oncology company that focuses on developing novel cancer therapies using a synthetic lethality approach. The company leverages its proprietary SNIPRx® platform, which employs genome-wide CRISPR-based screening to identify synthetic lethal gene pairs. This allows them to target specific genetic alterations in tumors, thereby developing highly targeted therapies for cancer patients (https:...
1
1
$Repare Therapeutics(RPTX.US$
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Repare Therapeutics announced positive initial data from their Phase 1 MINOTAUR trial, evaluating lunresertib in combination with FOLFIRI for advanced solid tumors.
The trial showed an overall response rate of 18.2% in heavily pretreated patients and a 51.5% clinical benefit rate. Among colorectal cancer (CRC) patients,...
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Repare Therapeutics announced positive initial data from their Phase 1 MINOTAUR trial, evaluating lunresertib in combination with FOLFIRI for advanced solid tumors.
The trial showed an overall response rate of 18.2% in heavily pretreated patients and a 51.5% clinical benefit rate. Among colorectal cancer (CRC) patients,...
1
$Repare Therapeutics(RPTX.US$
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
1
$Repare Therapeutics(RPTX.US$
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
Repare Therapeutics (Nasdaq: RPTX) announced that initial data from its Phase 1 MINOTAUR study will be presented at the European Society of Medical Oncology (ESMO) GI Congress 2024. The study evaluates the efficacy of lunresertib (RP-6306) in combination with FOLFIRI for treating advanced solid tumors. This presentation is scheduled for June 27, 2024, at 3:35 PM CEST in Munich...
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
Repare Therapeutics (Nasdaq: RPTX) announced that initial data from its Phase 1 MINOTAUR study will be presented at the European Society of Medical Oncology (ESMO) GI Congress 2024. The study evaluates the efficacy of lunresertib (RP-6306) in combination with FOLFIRI for treating advanced solid tumors. This presentation is scheduled for June 27, 2024, at 3:35 PM CEST in Munich...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
北美深蓝OP :
Add a warehouse